LiveSpo is a pioneer in R&D and manufacturing spore-based probiotics based on Bacillus Subtills and Bacillus Clausii. LiveSpo is a model of Vietnam based biotech R&D which have led to scientific breakthroughs on a global scale. A series of three clinical trials, all separately peer reviewed and published in the leading peer reviewed journal Scientific Reports, demonstrated that LiveSpo NAVAX, which utilizes bacillus subtills spores in a saline solution, applied to the respiratory tract, had a substantial impact on eliminating respiratory viral infections. This included shortened recovery times, symptom relief and significantly reduced viral load counts for acute respiratory syncytial virus (RSV)[1], influenza[2], and acute rhinosinusitis (ARS) and acute otitis media (AOM)[3]. Scientific Reports is a peer-reviewed scientific journal that belongs to the Nature Portfolio, which is a group of journals owned by the publisher Springer Nature.
Gene Solutions is a pioneer in gene-based disease detection at affordable prices. Their globally cutting-edge R&D team has developed a variety of tests for cancer detection, which are first of their kind of Asia and based on leading edge Next Generation Sequencing technology. Gene Solutions’ SPOT-MAS 10 is the first Multi Cancer Early Detection (MCED) test in Asia to provide real-world clinical evidence for cancer screening, offering the validation data needed for region-specific populations and demonstrating the test’s clinical utility. As reported in the peer reviewed journal BMC Medicine in February 2025, SPOT‑MAS ctDNA assay was evaluated in a landmark prospective cohort involving 9,024 asymptomatic Vietnamese adults, showing 70.8 % sensitivity for cancer detection (including precancerous lesions) and 99.7 % specificity, with 60 % positive predictive value for locating cancers[1] – making it Asia’s first clinically validated multi-cancer early detection blood test.